American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (986)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (940)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1255)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (311)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (62)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5172)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular predictors of disease progression to myelofibrosis (MF) in patients (Pts) with polycythemia vera (PV) enrolled in REVEAL
    Meeting Abstract

    Oh, S.; Zwicker, J. I.; Patel, K.; Crowgey, E. L.; Timmers, C.; Feldman, P.; Carl, J.; Hamer-Maansson, J. E.; Bhatt, V.; Braunstein, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Five-year survival of patients (pts) from Transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M.; Wang, M.; Arnason, J. E.; Kamdar, M.; Maloney, D. G.; Shadman, M.; Andreadis, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Bleeding in lung cancer patients receiving therapeutic anticoagulation while being treated with VEGF and EGFR inhibitors
    Meeting Abstract

    Fusillo, T. F.; Leader, A.; Mantha, S.; Ajufo, H.; Derkach, A.; Schoenfeld, A.; Singh, R.; Kaplinsky, P.; Zwicker, J. I.
    Blood (2024)

    Fulltext@MSK | Save
  • Investigating the novel combination of the innate cell engager (ICE®) acimtamig with off-the-shelf allogeneic natural killer cells AlloNK® in relapsed or refractory classical Hodgkin lymphoma (R/R cHL): Initial results of the phase 2 Luminice-203
    Meeting Abstract

    Maakaron, J.; Modi, D.; Mei, M. T.; Feldman, T.; Shah, G. L.; Mehta, A. N.; Sauter, C. S.; Khanal, R.; Barta, S. K.; Emig, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of efficacy and safety outcomes for lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for the treatment of third-line or later (3L+) relapsed or refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Boardman, A. P.; Reguera, J. L.; Spin, P.; Wang, P.; Almuallem, L.; Ellis, J.; Zheng, J.; Kumar, J.; Farazi, T.; García-Sancho, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • BP43131, a phase 1 dose escalation study: CD19 targeted CD28 costimulatory agonist (RO7443904) combined with glofitamab shows promising efficacy in patients with relapsed/refractory aggressive B-NHL
    Meeting Abstract

    Dickinson, M. J.; Hutchings, M.; Morschhauser, F.; Carlo-Stella, C.; Falchi, L.; Caimi, P. F.; Dimier, N.; Smith, L.; Whayman, M.; Sam, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Very low dose radiotherapy (VLDRT) with 4 Gy for potentially-curable indolent non-Hodgkin lymphomas
    Meeting Abstract

    Mankuzhy, N. P.; Imber, B. S.; Pammer, P.; Fregonese, B.; Cajo, A.; Cederquist, G.; Dreyfuss, A.; Lapen, K.; Patel, R. R.; Moore, Z. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Peripheral blood smear-based deep learning to predict cancer-associated thrombosis
    Meeting Abstract

    Dilip, D.; Singi, S.; Webb, D. C.; Colorado-Jimenez, C.; Singh, R.; Yin, Z.; Paulsen, S.; McVoy, L.; Fenelus, M.; Roshal, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save